Sequentia Biotech, a CataloniaBio & HealthTech member, and NextBiomics, a University of Naples Federico II spin-off, announced the filing of a patent application for a bacterial vaccine against COVID-19.
The NextBiomics vaccine is similar to others authorised (AstraZeneca, Johnson & Johnson, Moderna, Pfizer and Reithera) in that it stimulates an immune response against the Spike-
shaped protein that the coronavirus uses to infect cells, but its difference lies in using
a probiotic bacterium as a vector.
"The evolution of the SARS-CoV-2 pandemic indicates that citizens will have to continue to undergo the recall vaccination. The strength of our approach with oral administration is to make this process faster" says Walter Sanseverino, CEO of Sequentia Biotech, a Barcelona-based company with expertise in genomics and microbiomics.
They are having conversations with several pharmaceutical companies to carry out the clinical trials.
Photo: Walter Sanseverino
Comments